Find a Researcher

Identification and characterization of the oncogenic MUC1-C protein. The Kufe laboratory identified DF3/MUC1 in the 1980s as a glycoprotein that is aberrantly overexpressed in ~90% of human breast cancers. Cloning of the DF3/MUC1 gene further identified a unique physical structure comprised of 20 amino acid tandem repeats. Subsequent work showed that MUC1 is a complex consisting of an extracellular N-terminal subunit with glycosylated tandem repeats (MUC1-N; the mucin component) and a C-terminal transmembrane subunit (MUC1-C; the signaling component). In providing protection from the external environment, normal epithelial cells respond to stress with release of MUC1-N into the protective mucous barrier and MUC1-C functions in the transduction of signals to the interior of the cell to promote loss of polarity and induce wound healing and repair. Appropriation of this response by overexpression of MUC1-C, as found in carcinoma cells, was shown to be sufficient for inducing anchorage-independent growth and tumorigenicity, providing the first evidence that MUC1-C functions as an oncoprotein.

MUC1-C activates cell membrane and nuclear signaling pathways. Subsequent work demonstrated that MUC1-C drives loss of polarity, forms complexes with RTKs, such as EGFR, HER2 and others at the cell membrane, and contributes to their activation. These findings were extended by the demonstration that MUC1-C transduces signals from the cell membrane to the nucleus. As one example, MUC1-C was found to directly activate the proinflammatory IKK→NF-κB→p65 pathway, form complexes with p65 on promoters of target genes and contribute to their regulation. Other work showed that MUC1-C promotes the inflammatory response through activation of nuclear STAT1/3 signaling pathways, supporting the notion that MUC1-C contributes to the association between inflammation and cancer.

MUC1-C induces EMT, self-renewal and epigenetic reprogramming. The Kufe laboratory first demonstrated that MUC1-C functions in the regulation of genes that drive EMT and self-renewal of cancer stem-like cells. Further work linked MUC1-C to epigenetic reprogramming by showing that MUC1-C regulates DNA methylation by activating the DNMT1 and DNMT3b genes. Advances also included unrecognized roles for MUC1-C in activating the PRC1/BMI1 and PRC2/EZH2 complexes in driving the repression of tumor suppressor genes, such as CHD1, CDKN2A, PTEN, BRCA1 and RASSF1A. Other studies showed that MUC1-C activates the highly conserved NuRD complex, which regulates chromatin assembly and reorganization and is of importance for EMT and invasion. These findings linked MUC1-C to integrating DNA methylation, histone regulation and chromatin remodeling in cancer cells.

MUC1-C promotes genotoxic and targeted drug resistance. The early finding that MUC1-C confers resistance to genotoxic anti-cancer agents was attributed in part to suppression of the DNA damage-induced apoptotic response. Other work in this area extended involvement of MUC1-C in the repair of DNA damage and, more recently, the integration of chromatin remodeling in that response. Other studies showed that MUC1-C confers resistance to targeted agents, such as trastuzumab, tamoxifen, afatinib and others, and that targeting MUC1-C is synergistic with these agents in resistant cells.

MUC1-C inhibits immune recognition and destruction. The Kufe laboratory first demonstrated that MUC1-C activates the PD-L1 gene and represses expression of immune effectors in cancer cells. In concert with these functions, targeting MUC1-C with a novel inhibitor downregulates PD-L1 in mouse tumor models and activates CD8+ T-cells in the immune microenvironment. In addition, MUC1 expression in human cancers correlates negatively with that of the CD8 and IFNγ genes and is associated with poor clinical outcomes. These findings provided the first evidence that MUC1-C plays a role in immune evasion.

MUC1-C drives dedifferentiation and pluripotency cancer cells. Understanding how MUC1-C drives cancer cell plasticity and the multiple above hallmarks of the cancer cell is of critical importance. The Kufe laboratory has found that MUC1-C induces dedifferentiation and pluripotency of breast and prostate cancer cells. In this way, MUC1-C drives stemness in association with induction of Yamanaka pluripotency factors, which have been shown to confer lineage plasticity and dedifferentiation of fibroblasts. These findings have uncovered new lines of ongoing investigation to more precisely define how MUC1-C integrates dedifferentiation, stemness and pluripotency in cancer.

Targeting MUC1-C with agents under development. There are presently no clinically available therapeutic agents against the MUC1-C subunit. To address this unmet need, the Kufe laboratory has developed potential therapeutics that target the MUC1-C extracellular and cytoplasmic domains. The generation of monoclonal antibodies (mAbs) against the MUC1-C extracellular domain provided the basis for development of CAR T-cells, BiTEs and antibody-drug conjugates. A cell-penetrating peptide directed against the MUC1-C cytoplasmic domain CQC motif, which is necessary for MUC1-C homodimerization and oncogenic function, is also under development with NCI Moonshot funding based on its activity in suppressing MUC1-C-induced drug resistance and immune evasion.

Please view a timeline of Kufe lab discoveries on our lab website for more information about our work.

MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer. Cancer Lett. 2023 04 10; 559:216116.
View in: PubMed

MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer. Mol Cancer Res. 2023 03 01; 21(3):274-289.
View in: PubMed

Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer. Int J Mol Sci. 2023 Feb 13; 24(4).
View in: PubMed

MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells. J Immunother Cancer. 2023 02; 11(2).
View in: PubMed

Emergence of MUC1 in Mammals for Adaptation of Barrier Epithelia. Cancers (Basel). 2022 Sep 30; 14(19).
View in: PubMed

Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer. Mol Cancer Res. 2022 09 02; 20(9):1379-1390.
View in: PubMed

Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression. Int J Mol Sci. 2022 Jul 26; 23(15).
View in: PubMed

Personalized tumor vaccine for pancreatic cancer. Cancer Immunol Immunother. 2023 Feb; 72(2):301-313.
View in: PubMed

Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. Oncogene. 2022 07; 41(27):3511-3523.
View in: PubMed

Targeting MUC1-C Suppresses Chronic Activation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer. Cancers (Basel). 2022 May 24; 14(11).
View in: PubMed

MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells. Mol Cancer Res. 2022 04 01; 20(4):556-567.
View in: PubMed

Chronic activation of MUC1-C in wound repair promotes progression to cancer stem cells. J Cancer Metastasis Treat. 2022; 8.
View in: PubMed

MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas. Carcinogenesis. 2022 02 11; 43(1):67-76.
View in: PubMed

MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer. Oncoimmunology. 2022; 11(1):2029298.
View in: PubMed

Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer. Theranostics. 2022; 12(3):999-1011.
View in: PubMed

The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. Front Immunol. 2021; 12:735609.
View in: PubMed

MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells. Oncogene. 2021 07; 40(30):4930-4940.
View in: PubMed

Correction: Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2021 May; 40(18):3347.
View in: PubMed

Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 05 01; 106(5):1330-1342.
View in: PubMed

MUC1-C integrates activation of the IFN-? pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. J Immunother Cancer. 2021 01; 9(1).
View in: PubMed

MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. Cancer Res. 2021 02 15; 81(4):1111-1122.
View in: PubMed

MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis. 2020 09 24; 41(9):1173-1183.
View in: PubMed

Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. Cancer Sci. 2020 Oct; 111(10):3639-3652.
View in: PubMed

Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 12 01; 108(5):1380-1389.
View in: PubMed

MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight. 2020 06 18; 5(12).
View in: PubMed

Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. J Immunother Cancer. 2020 06; 8(1).
View in: PubMed

Author Correction: MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 Feb 24; 11(1):1095.
View in: PubMed

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338.
View in: PubMed

Correction: MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. Oncogene. 2019 Nov; 38(47):7278.
View in: PubMed

MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. Cancer Res. 2019 11 15; 79(22):5711-5722.
View in: PubMed

MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells. Oncogene. 2019 11; 38(47):7266-7277.
View in: PubMed

Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 10; 18(10):1744-1754.
View in: PubMed

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine. Br J Haematol. 2019 05; 185(4):679-690.
View in: PubMed

MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells. Cancer Res. 2019 04 15; 79(8):2031-2041.
View in: PubMed

Corrigendum to 'Concomitant delivery of paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy' NANO 14 (2018) 1301-1313. Nanomedicine. 2018 10; 14(7):2129.
View in: PubMed

Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight. 2018 06 21; 3(12).
View in: PubMed

MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J Cell Mol Med. 2018 Aug; 22(8):3887-3898.
View in: PubMed

Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. Signal Transduct Target Ther. 2018; 3:13.
View in: PubMed

Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. Nanomedicine. 2018 06; 14(4):1301-1313.
View in: PubMed

MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. Oncogene. 2018 04; 37(16):2079-2088.
View in: PubMed

MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. Cancer Res. 2018 01 01; 78(1):205-215.
View in: PubMed

CBP501 induces immunogenic tumor cell death and CD8 T cell infiltration into tumors in combination with platinum, and increases the efficacy of immune checkpoint inhibitors against tumors in mice. Oncotarget. 2017 Oct 03; 8(45):78277-78288.
View in: PubMed

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget. 2017 Sep 19; 8(41):69237-69249.
View in: PubMed

MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep. 2017 08 07; 7(1):7481.
View in: PubMed

Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Mol Cancer Ther. 2017 10; 16(10):2304-2314.
View in: PubMed

CBP501 suppresses macrophage induced cancer stem cell like features and metastases. Oncotarget. 2017 Sep 08; 8(38):64015-64031.
View in: PubMed

MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. Oncoimmunology. 2017; 6(9):e1338998.
View in: PubMed

MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926.
View in: PubMed

CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding. Oncotarget. 2017 Sep 26; 8(43):74006-74018.
View in: PubMed

CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to Calmodulin binding. Oncotarget. 2017 Jun 22.
View in: PubMed

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017 12; 31(12):2780-2790.
View in: PubMed

Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. Nanomedicine. 2017 07; 13(5):1833-1839.
View in: PubMed

MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. Biochim Biophys Acta Rev Cancer. 2017 Aug; 1868(1):117-122.
View in: PubMed

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017 07 13; 36(28):4037-4046.
View in: PubMed

Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Mol Cancer. 2017 02 02; 16(1):33.
View in: PubMed

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017 Mar 30; 129(13):1791-1801.
View in: PubMed

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
View in: PubMed

MUC1-C drives DNA methylation in cancer. Aging (Albany NY). 2016 12 28; 8(12):3155-3156.
View in: PubMed

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
View in: PubMed

Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-ß-Dependent Activation of Antigen-specific CD8+ T Cells. Mol Ther. 2010 May; 18(5):912-920.
View in: PubMed

MUC1-C activates BMI1 in human cancer cells. Oncogene. 2017 05 18; 36(20):2791-2801.
View in: PubMed

MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. Mol Cancer Res. 2016 12; 14(12):1266-1276.
View in: PubMed

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016 09 08; 1(14):e89014.
View in: PubMed

MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987.
View in: PubMed

MUC1 in hematological malignancies. Leuk Lymphoma. 2016 11; 57(11):2489-98.
View in: PubMed

MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. Sci Rep. 2016 05 24; 6:26643.
View in: PubMed

DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. Oncogene. 2016 12 15; 35(50):6439-6445.
View in: PubMed

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016 Mar 15; 7(11):11756-69.
View in: PubMed

MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97.
View in: PubMed

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas. Cancer Res. 2016 Mar 15; 76(6):1538-48.
View in: PubMed

Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156.
View in: PubMed

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 2015 Jul 16; 126(3):354-62.
View in: PubMed

Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. Clin Cancer Res. 2015 May 15; 21(10):2338-47.
View in: PubMed

MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015 Oct 01; 34(40):5187-97.
View in: PubMed

MUC1-C Induces the LIN28B?LET-7?HMGA2 Axis to Regulate Self-Renewal in NSCLC. Mol Cancer Res. 2015 Mar; 13(3):449-60.
View in: PubMed

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget. 2014 Oct 15; 5(19):8893-905.
View in: PubMed

CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway. Mol Cancer Ther. 2014 Dec; 13(12):3013-23.
View in: PubMed

Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res. 2014 Nov 01; 20(21):5423-34.
View in: PubMed

Activation of Nrf2 pathways correlates with resistance of NSCLC cell lines to CBP501 in vitro. Mol Cancer Ther. 2014 Sep; 13(9):2215-25.
View in: PubMed

Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget. 2014 May 15; 5(9):2622-34.
View in: PubMed

Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res. 2014 Jun 15; 74(12):3271-81.
View in: PubMed

Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood. 2014 May 08; 123(19):2997-3006.
View in: PubMed

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42.
View in: PubMed

MUC1-C oncoprotein activates ERK?C/EBPß signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. J Biol Chem. 2013 Oct 25; 288(43):30892-903.
View in: PubMed

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene. 2014 Jun 26; 33(26):3422-31.
View in: PubMed

MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res. 2013 Sep 01; 73(17):5569-79.
View in: PubMed

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
View in: PubMed

MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene. 2014 Mar 27; 33(13):1680-9.
View in: PubMed

Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer. Mol Cancer Res. 2013 Jul; 11(7):714-23.
View in: PubMed

Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. Cancer Biol Ther. 2013 Feb; 14(2):127-34.
View in: PubMed

Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). J Immunother. 2012 Sep; 35(7):555-69.
View in: PubMed

Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One. 2012; 7(7):e39432.
View in: PubMed

Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
View in: PubMed

Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2013 Apr 25; 32(17):2179-88.
View in: PubMed

Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol. 2012 Jun; 39(3):287-95.
View in: PubMed

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406.
View in: PubMed

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013 Feb 28; 32(9):1073-81.
View in: PubMed

The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem. 2012 Jun 15; 287(25):20866-75.
View in: PubMed

MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate. 2012 Nov; 72(15):1659-68.
View in: PubMed

MUC1-C oncoprotein induces TCF7L2 transcription factor activation and promotes cyclin D1 expression in human breast cancer cells. J Biol Chem. 2012 Mar 23; 287(13):10703-10713.
View in: PubMed

Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol. 2012 May; 40(5):1643-9.
View in: PubMed

A monoclonal antibody against the oncogenic mucin 1 cytoplasmic domain. Hybridoma (Larchmt). 2011 Dec; 30(6):531-5.
View in: PubMed

MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS One. 2011; 6(11):e28234.
View in: PubMed

Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood. 2012 Jan 19; 119(3):810-6.
View in: PubMed

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011 Oct 06; 118(14):3922-31.
View in: PubMed

CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin. Mol Cancer Ther. 2011 Oct; 10(10):1929-38.
View in: PubMed

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun; 34(5):409-18.
View in: PubMed

MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70.
View in: PubMed

Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011 May; 10(5):806-16.
View in: PubMed

Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors. Mol Pharmacol. 2011 May; 79(5):886-93.
View in: PubMed

MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 2011 Feb 15; 4(160):ra9.
View in: PubMed

Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells. Prostate. 2011 Sep; 71(12):1299-308.
View in: PubMed

Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res. 2011 May 15; 17(10):3431-42.
View in: PubMed

MUC1-C Oncoprotein Blocks Terminal Differentiation of Chronic Myelogenous Leukemia Cells by a ROS-Mediated Mechanism. Genes Cancer. 2011 Jan; 2(1):56-64.
View in: PubMed

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
View in: PubMed

Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010 Sep 01; 10(5):483-91.
View in: PubMed

Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene. 2010 Oct 21; 29(42):5663-6.
View in: PubMed

miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. Int J Oncol. 2010 Jul; 37(1):61-9.
View in: PubMed

Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res. 2010 Jul; 8(7):986-93.
View in: PubMed

MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
View in: PubMed

Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010 Aug; 78(2):166-74.
View in: PubMed

Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20.
View in: PubMed

MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation. Genes Cancer. 2010 Mar; 1(3):239-250.
View in: PubMed

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66.
View in: PubMed

Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep; 45(9):1463-8.
View in: PubMed

MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR-125b ONCOMIR. Genes Cancer. 2010 Jan 01; 1(1):62-68.
View in: PubMed

Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009 Dec; 9(12):874-85.
View in: PubMed

Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010 Feb 11; 29(6):920-9.
View in: PubMed

MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 2009 Nov; 8(11):3056-65.
View in: PubMed

MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009 Sep 01; 69(17):7013-21.
View in: PubMed

Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther. 2009 Jul; 8(13):1197-203.
View in: PubMed

Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009 Jun 15; 69(12):5133-41.
View in: PubMed

MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol. 2009 Jun; 34(6):1691-9.
View in: PubMed

Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 2009 Aug; 16(8):609-19.
View in: PubMed

MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009 Apr 01; 69(7):2833-7.
View in: PubMed

MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5837-41.
View in: PubMed

MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther. 2008 Dec; 7(12):1959-67.
View in: PubMed

Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
View in: PubMed

MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res. 2008 Aug 01; 68(15):6136-44.
View in: PubMed

MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol. 2008 Jul; 33(1):153-9.
View in: PubMed

Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol. 2008 Jul 01; 181(1):808-21.
View in: PubMed

Immunologic effects of sunitinib in renal cell carcinoma. J Clin Oncol. 2008 May 20; 26(15_suppl):14551.
View in: PubMed

Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res. 2008 Apr 15; 68(8):2920-6.
View in: PubMed

Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer Biol Ther. 2008 Jan; 7(1):81-4.
View in: PubMed

MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007 Dec 15; 67(24):11576-84.
View in: PubMed

Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB. Int J Oncol. 2007 Dec; 31(6):1519-28.
View in: PubMed

MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol. 2007 Dec; 9(12):1419-27.
View in: PubMed

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007 Oct; 30(7):749-61.
View in: PubMed

The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007 Sep 21; 27(6):992-1004.
View in: PubMed

Evolution of the human MUC1 oncoprotein. Int J Oncol. 2007 Sep; 31(3):671-7.
View in: PubMed

Inhibition of nuclear factor-kappaB activity by temozolomide involves O6-methylguanine induced inhibition of p65 DNA binding. Cancer Res. 2007 Jul 15; 67(14):6889-98.
View in: PubMed

Cockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase. Nucleic Acids Res. 2007; 35(15):4941-51.
View in: PubMed

Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem. 2007 Jul 06; 282(27):19321-30.
View in: PubMed

Human mucin 1 oncoprotein represses transcription of the p53 tumor suppressor gene. Cancer Res. 2007 Feb 15; 67(4):1853-8.
View in: PubMed

Novel compounds with antiproliferative activity against imatinib-resistant cell lines. Mol Cancer Ther. 2007 Feb; 6(2):655-66.
View in: PubMed

Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint. Mol Cancer Ther. 2007 Jan; 6(1):147-53.
View in: PubMed

Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. J Biol Chem. 2007 Jan 05; 282(1):257-66.
View in: PubMed

MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res. 2006 Nov; 4(11):873-83.
View in: PubMed

Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem. 2006 Nov 24; 281(47):35764-9.
View in: PubMed

MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 2006 Aug 23; 25(16):3774-83.
View in: PubMed

A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. Cancer Chemother Pharmacol. 2007 Feb; 59(3):329-35.
View in: PubMed

Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene. 2006 May 24; 373:28-34.
View in: PubMed

MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell. 2006 Jan 20; 21(2):295-305.
View in: PubMed

MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90. Oncogene. 2006 Jan 05; 25(1):20-31.
View in: PubMed

Ionizing radiation: a genetic switch for cancer therapy. Cancer Gene Ther. 2006 Jan 01; 13(1):1-6.
View in: PubMed

MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005 Nov 15; 65(22):10413-22.
View in: PubMed

Chemo-inducible gene therapy. Anticancer Drugs. 2005 Nov; 16(10):1053-8.
View in: PubMed

The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. Cancer Chemother Pharmacol. 2005 Dec; 56(6):610-4.
View in: PubMed

Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700.
View in: PubMed

Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemother Pharmacol. 2005 Sep; 56(3):317-21.
View in: PubMed

Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells. Cell Death Differ. 2005 May; 12(5):523-31.
View in: PubMed

Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther. 2005 May; 5(5):703-15.
View in: PubMed

Ubiquitination and degradation of the Arg tyrosine kinase is regulated by oxidative stress. Oncogene. 2005 Apr 07; 24(15):2433-40.
View in: PubMed

Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest. 2005 Apr; 35(4):279-86.
View in: PubMed

JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol. 2005 Mar; 7(3):278-85.
View in: PubMed

Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism. J Immunol. 2005 Feb 15; 174(4):2376-86.
View in: PubMed

Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell. 2005 Feb; 7(2):167-78.
View in: PubMed

c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage. J Biol Chem. 2005 Mar 25; 280(12):11147-51.
View in: PubMed

Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res. 2004 Dec; 28(12):1303-12.
View in: PubMed

2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells. Cancer Res. 2004 Dec 01; 64(23):8512-6.
View in: PubMed

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004 Nov-Dec; 27(6):452-9.
View in: PubMed

Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma. Cancer Res. 2004 Sep 15; 64(18):6381-4.
View in: PubMed

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004 Sep 01; 10(17):5747-53.
View in: PubMed

Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activity. Mol Cancer Ther. 2004 Sep; 3(9):1167-75.
View in: PubMed

Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice. Int J Cancer. 2004 Aug 20; 111(2):238-45.
View in: PubMed

MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem. 2004 Oct 29; 279(44):45721-7.
View in: PubMed

Interim safety and efficacy results from a phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):2526.
View in: PubMed

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004 Jul 15; 10(14):4699-708.
View in: PubMed

Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest. 2004 May; 113(9):1307-17.
View in: PubMed

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
View in: PubMed

Antitumor effects of fusions composed of dendritic cells and fibroblasts transfected with genomic DNA from tumor cells. Cancer Immunol Immunother. 2004 Aug; 53(8):690-6.
View in: PubMed

Interaction of human MUC1 and beta-catenin is regulated by Lck and ZAP-70 in activated Jurkat T cells. Biochem Biophys Res Commun. 2004 Mar 05; 315(2):471-6.
View in: PubMed

The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem. 2004 May 14; 279(20):20607-12.
View in: PubMed

Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004 Feb; 5(2):163-75.
View in: PubMed

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15; 22(4):592-601.
View in: PubMed

Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. Mol Cancer Ther. 2004 Jan; 3(1):39-45.
View in: PubMed

Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors. Clin Cancer Res. 2003 Nov 01; 9(14):5178-86.
View in: PubMed

MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther. 2003 Nov-Dec; 2(6):702-6.
View in: PubMed

Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur J Clin Invest. 2003 Oct; 33(10):897-904.
View in: PubMed

Catalase is regulated by ubiquitination and proteosomal degradation. Role of the c-Abl and Arg tyrosine kinases. Biochemistry. 2003 Sep 09; 42(35):10348-53.
View in: PubMed

Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 2003 Sep 04; 22(38):6107-10.
View in: PubMed

Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution. Mol Cell Biol. 2003 Sep; 23(18):6385-95.
View in: PubMed

The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res. 2003 Sep 01; 63(17):5551-8.
View in: PubMed

Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003 Aug; 1(10):765-75.
View in: PubMed

Glutathione peroxidase 1 is regulated by the c-Abl and Arg tyrosine kinases. J Biol Chem. 2003 Oct 10; 278(41):39609-14.
View in: PubMed

Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther. 2003 Jul-Aug; 2(4):326-9.
View in: PubMed

Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem. 2003 Sep 12; 278(37):35458-64.
View in: PubMed

Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology. 2003 Jun; 109(2):300-7.
View in: PubMed

Catalase activity is regulated by c-Abl and Arg in the oxidative stress response. J Biol Chem. 2003 Aug 08; 278(32):29667-75.
View in: PubMed

Protein kinase Cdelta is responsible for constitutive and DNA damage-induced phosphorylation of Rad9. EMBO J. 2003 Mar 17; 22(6):1431-41.
View in: PubMed

DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol Ther. 2003 Mar-Apr; 2(2):187-93.
View in: PubMed

Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response. J Biol Chem. 2003 Apr 11; 278(15):12961-7.
View in: PubMed

Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther. 2003 Feb; 10(3):206-12.
View in: PubMed

Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol Pharmacol. 2003 Feb; 63(2):276-82.
View in: PubMed

Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J Gastroenterol. 2003; 38(10):989-94.
View in: PubMed

Update on cancer vaccines. Curr Opin Gastroenterol. 2002 Nov; 18(6):723-31.
View in: PubMed

Lyn tyrosine kinase inhibits nuclear export of the p53 tumor suppressor. Cancer Biol Ther. 2002 Nov-Dec; 1(6):703-8.
View in: PubMed

Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002 Nov; 3(11):665-71.
View in: PubMed

Activation of SAPK/JNK signaling by protein kinase Cdelta in response to DNA damage. J Biol Chem. 2002 Dec 13; 277(50):48372-8.
View in: PubMed

Angiostatin potentiates cyclophosphamide treatment of metastatic disease. Cancer Chemother Pharmacol. 2002 Nov; 50(5):412-8.
View in: PubMed

Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002 Sep 15; 20(18):3772-84.
View in: PubMed

Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug; 110(3):403-10.
View in: PubMed

p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. J Biol Chem. 2002 Sep 13; 277(37):33758-65.
View in: PubMed

Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 2002 Jun; 61(6):1489-95.
View in: PubMed

Manganese superoxide dismutase (SOD2) inhibits radiation-induced apoptosis by stabilization of the mitochondrial membrane. Radiat Res. 2002 May; 157(5):568-77.
View in: PubMed

c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage. Mol Cell Biol. 2002 May; 22(10):3292-300.
View in: PubMed

Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002 Apr 01; 99(7):2512-7.
View in: PubMed

Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem. 2002 May 17; 277(20):17616-22.
View in: PubMed

The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol. 2002 Mar 01; 168(5):2111-7.
View in: PubMed

Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res. 2002 Feb 01; 62(3):789-95.
View in: PubMed

Tumor production of angiostatin is enhanced after exposure to TNF-alpha. Int J Cancer. 2002 Feb 01; 97(4):410-5.
View in: PubMed

Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 2002 Jan-Feb; 8(1):47-54.
View in: PubMed

Negative regulation of the SHPTP1 protein tyrosine phosphatase by protein kinase C delta in response to DNA damage. Mol Pharmacol. 2001 Dec; 60(6):1431-8.
View in: PubMed

Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol. 2001 Nov; 101(2):192-200.
View in: PubMed

The novel isocoumarin 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) propionic acid (NM-3) induces lethality of human carcinoma cells by generation of reactive oxygen species. Mol Cancer Ther. 2001 Nov; 1(1):43-8.
View in: PubMed

Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol. 2001 Nov; 48(5):347-55.
View in: PubMed

Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol. 2001 Nov; 36(11):764-71.
View in: PubMed

Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol. 2001 Oct; 11(4):338-45.
View in: PubMed

Targeting of protein kinase C delta to mitochondria in the oxidative stress response. Cell Growth Differ. 2001 Sep; 12(9):465-70.
View in: PubMed

Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Mol Cell Biol. 2001 Sep; 21(18):6233-42.
View in: PubMed

Mitochondrial targeting of JNK/SAPK in the phorbol ester response of myeloid leukemia cells. Cell Death Differ. 2001 Aug; 8(8):794-800.
View in: PubMed

The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem. 2001 Sep 21; 276(38):35239-42.
View in: PubMed

Angiostatin effects on endothelial cells mediated by ceramide and RhoA. EMBO Rep. 2001 Jun; 2(6):536-40.
View in: PubMed

Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody. Cancer Res. 2001 May 15; 61(10):4061-5.
View in: PubMed

The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol. 2001 May; 59(5):1094-9.
View in: PubMed

Targeting of the c-Abl tyrosine kinase to mitochondria in the necrotic cell death response to oxidative stress. J Biol Chem. 2001 May 18; 276(20):17281-5.
View in: PubMed

The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Biochem Biophys Res Commun. 2001 Feb 23; 281(2):440-3.
View in: PubMed

The ARG tyrosine kinase interacts with Siva-1 in the apoptotic response to oxidative stress. J Biol Chem. 2001 Apr 13; 276(15):11465-8.
View in: PubMed

Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. J Clin Oncol. 2001 Feb 01; 19(3):857-69.
View in: PubMed

Interaction of hematopoietic progenitor kinase 1 and c-Abl tyrosine kinase in response to genotoxic stress. J Biol Chem. 2001 May 25; 276(21):18130-8.
View in: PubMed

The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem. 2001 Mar 02; 276(9):6061-4.
View in: PubMed

Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 2001; 40(6):735-8.
View in: PubMed

Phorbol ester-induced generation of reactive oxygen species is protein kinase cbeta -dependent and required for SAPK activation. J Biol Chem. 2000 Dec 29; 275(52):41000-3.
View in: PubMed

NM-3, an isocoumarin, increases the antitumor effects of radiotherapy without toxicity. Cancer Res. 2000 Dec 15; 60(24):6958-63.
View in: PubMed

Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol. 2000 Nov 15; 165(10):5713-9.
View in: PubMed

Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology. 2000 Nov; 101(3):316-24.
View in: PubMed

XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem. 2000 Oct 13; 275(41):31733-8.
View in: PubMed

Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000 Sep-Oct; 6(5):287-93.
View in: PubMed

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest. 2000 Sep; 106(6):763-71.
View in: PubMed

Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J. 2000 Aug 15; 19(16):4310-22.
View in: PubMed

Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells. Oncogene. 2000 Aug 10; 19(34):3941-7.
View in: PubMed

Role for Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage. Mol Cell Biol. 2000 Aug; 20(15):5370-80.
View in: PubMed

Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol. 2000 Aug 01; 165(3):1705-11.
View in: PubMed

Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. J Biol Chem. 2000 Jul 21; 275(29):21793-6.
View in: PubMed

Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplant. 2000 Jul; 26(2):169-76.
View in: PubMed

Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol. 2000 Jul; 20(14):4979-89.
View in: PubMed

Proteolytic cleavage and activation of protein kinase C [micro] by caspase-3 in the apoptotic response of cells to 1-beta -D-arabinofuranosylcytosine and other genotoxic agents. J Biol Chem. 2000 Jun 16; 275(24):18476-81.
View in: PubMed

Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem. 2000 Jun 09; 275(23):17237-40.
View in: PubMed

Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol. 2000 May 18; 10(10):568-75.
View in: PubMed

Angiostatin induces mitotic cell death of proliferating endothelial cells. Mol Cell Biol Res Commun. 2000 May; 3(5):277-82.
View in: PubMed

The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ. 2000 May; 11(5):261-7.
View in: PubMed

Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 2000 May 01; 60(9):2520-6.
View in: PubMed

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res. 2000 May; 6(5):1632-8.
View in: PubMed

Regulation of the rapamycin and FKBP-target 1/mammalian target of rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase. J Biol Chem. 2000 Apr 14; 275(15):10779-87.
View in: PubMed

Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene. 2000 Apr 13; 19(16):1975-81.
View in: PubMed

Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol. 2000 Apr; 57(4):792-6.
View in: PubMed

Interaction between protein kinase C delta and the c-Abl tyrosine kinase in the cellular response to oxidative stress. J Biol Chem. 2000 Mar 17; 275(11):7470-3.
View in: PubMed

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci U S A. 2000 Mar 14; 97(6):2715-8.
View in: PubMed

Functional interaction between RAFT1/FRAP/mTOR and protein kinase cdelta in the regulation of cap-dependent initiation of translation. EMBO J. 2000 Mar 01; 19(5):1087-97.
View in: PubMed

Smallpox, polio and now a cancer vaccine? Nat Med. 2000 Mar; 6(3):252-3.
View in: PubMed

In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
View in: PubMed

Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. J Biol Chem. 2000 Jan 07; 275(1):322-7.
View in: PubMed

A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Cancer Chemother Pharmacol. 2000; 46(4):319-28.
View in: PubMed

Functional interaction between SHPTP1 and the Lyn tyrosine kinase in the apoptotic response to DNA damage. J Biol Chem. 1999 Dec 03; 274(49):34663-8.
View in: PubMed

Function for p300 and not CBP in the apoptotic response to DNA damage. Oncogene. 1999 Oct 07; 18(41):5714-7.
View in: PubMed

Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation. Int J Oncol. 1999 Oct; 15(4):769-73.
View in: PubMed

Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999 Oct; 5(10):2735-41.
View in: PubMed

Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999 Jul 15; 59(14):3374-8.
View in: PubMed

p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999 Jun 24; 399(6738):814-7.
View in: PubMed

In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res. 1999 May 01; 59(9):2121-6.
View in: PubMed

Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. Mol Cell Biol. 1999 Apr; 19(4):2986-97.
View in: PubMed

Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999 Mar 01; 93(5):1487-95.
View in: PubMed

The presence of the Rb c-box peptide in the cytoplasm inhibits p210bcr-abl transforming function. Oncogene. 1999 Feb 25; 18(8):1589-95.
View in: PubMed

Radiation-inducible gene therapy. C R Acad Sci III. 1999 Feb-Mar; 322(2-3):225-8.
View in: PubMed

Role for p300 in stabilization of p53 in the response to DNA damage. J Biol Chem. 1999 Jan 22; 274(4):1883-6.
View in: PubMed

Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig. 1999; 7(5):261-9.
View in: PubMed

Functional role for protein kinase Cbeta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells. Mol Cell Biol. 1999 Jan; 19(1):461-70.
View in: PubMed

Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene. 1998 Dec 24; 17(25):3309-18.
View in: PubMed

Adenovirus vector-based purging of multiple myeloma cells. Blood. 1998 Dec 15; 92(12):4591-601.
View in: PubMed

Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998 Dec 15; 58(24):5686-9.
View in: PubMed

Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol. 1998 Dec; 18(12):7216-24.
View in: PubMed

Inactivation of DNA-dependent protein kinase by protein kinase Cdelta: implications for apoptosis. Mol Cell Biol. 1998 Nov; 18(11):6719-28.
View in: PubMed

Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998 Nov-Dec; 5(6):344-9.
View in: PubMed

Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. Oncogene. 1998 Oct 15; 17(15):1889-92.
View in: PubMed

Regulation of DNA-dependent protein kinase by the Lyn tyrosine kinase. J Biol Chem. 1998 Oct 02; 273(40):25654-8.
View in: PubMed

Phase II study of adozelesin in untreated metastatic breast cancer. Anticancer Drugs. 1998 Oct; 9(9):779-82.
View in: PubMed

Modulation of apoptotic response of a radiation-resistant human carcinoma by Pseudomonas exotoxin-chimeric protein. Cancer Res. 1998 Aug 01; 58(15):3215-20.
View in: PubMed

Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998 Jul 16; 394(6690):287-91.
View in: PubMed

Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem. 1998 Jul 03; 273(27):16647-50.
View in: PubMed

Antagonistic effects of ABL and BCRABL proteins on proliferation and the response to genotoxic stress in normal and leukemic myeloid cells. Leuk Lymphoma. 1998 Jul; 30(3-4):225-35.
View in: PubMed

Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther. 1998 Jul 01; 9(10):1409-17.
View in: PubMed

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A. 1998 May 26; 95(11):6279-83.
View in: PubMed

Functional role for the c-Abl tyrosine kinase in meiosis I. Oncogene. 1998 Apr 09; 16(14):1773-7.
View in: PubMed

Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene. 1998 Apr 02; 16(13):1643-8.
View in: PubMed

Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 1998 Mar; 5(3):293-300.
View in: PubMed

Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem. 1998 Feb 13; 273(7):3799-802.
View in: PubMed

Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res. 1998 Feb; 4(2):317-24.
View in: PubMed

Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J Biol Chem. 1997 Nov 28; 272(48):29995-7.
View in: PubMed

Functional role for the c-Abl protein tyrosine kinase in the cellular response to genotoxic stress. Biochim Biophys Acta. 1997 Oct 24; 1333(2):O1-7.
View in: PubMed

Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine. Oncogene. 1997 Oct 16; 15(16):1947-52.
View in: PubMed

Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit. J Biol Chem. 1997 Oct 03; 272(40):24763-6.
View in: PubMed

Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997 Oct; 3(10):1145-9.
View in: PubMed

Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 1997 Oct 01; 57(19):4205-9.
View in: PubMed

Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 1997 Oct; 4(10):1023-8.
View in: PubMed

Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. 1997 Oct 01; 57(19):4340-7.
View in: PubMed

Inhibition of phosphatidylinositol 3-kinase by c-Abl in the genotoxic stress response. J Biol Chem. 1997 Sep 19; 272(38):23485-8.
View in: PubMed

Caspase-3-mediated cleavage of protein kinase C theta in induction of apoptosis. J Biol Chem. 1997 Aug 15; 272(33):20317-20.
View in: PubMed

Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol. 1997 Jul 01; 159(1):351-9.
View in: PubMed

Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci U S A. 1997 Jun 24; 94(13):6939-42.
View in: PubMed

Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 1997 May 29; 387(6632):520-3.
View in: PubMed

Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem. 1997 May 09; 272(19):12492-4.
View in: PubMed

Gene therapy of cancer. Lancet. 1997 May; 349 Suppl 2:SII10-2.
View in: PubMed

Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997 May; 3(5):558-61.
View in: PubMed

Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature. 1997 Apr 17; 386(6626):732-5.
View in: PubMed

Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem Pharmacol. 1997 Apr 04; 53(7):1019-27.
View in: PubMed

Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 1997 Apr 01; 57(7):1270-5.
View in: PubMed

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med. 1997 Apr; 3(4):437-42.
View in: PubMed

Detection of the circulating lung cancer marker LCAP with a new monoclonal antibody TRD-L1. Int J Biol Markers. 1997 Apr-Jun; 12(2):49-54.
View in: PubMed

Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci U S A. 1997 Feb 18; 94(4):1437-40.
View in: PubMed

Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis. J Biol Chem. 1997 Jan 17; 272(3):1965-9.
View in: PubMed

Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997 Jan 01; 89(1):227-34.
View in: PubMed

Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother. 1997 Jan; 20(1):38-47.
View in: PubMed

Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55.
View in: PubMed

Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin. Ann N Y Acad Sci. 1996 Dec 13; 803:111-27.
View in: PubMed

Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest. 1996 Dec 01; 98(11):2539-48.
View in: PubMed

Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med. 1996 Dec 01; 184(6):2399-404.
View in: PubMed

Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med. 1996 Dec; 2(12):1367-70.
View in: PubMed

Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53. J Biol Chem. 1996 Oct 25; 271(43):26457-60.
View in: PubMed

Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. J Biol Chem. 1996 Sep 27; 271(39):23775-9.
View in: PubMed

Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood. 1996 Sep 15; 88(6):1936-43.
View in: PubMed

Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylcytosine. Oncogene. 1996 Sep 05; 13(5):939-46.
View in: PubMed

Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2. Cancer Res. 1996 Aug 15; 56(16):3617-21.
View in: PubMed

Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature. 1996 Jul 18; 382(6588):272-4.
View in: PubMed

The stress response to ionizing radiation involoves c-Abl-dependent phosphorylation of SHPTP1. Proc Natl Acad Sci U S A. 1996 Jul 09; 93(14):6898-901.
View in: PubMed

Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. Gene Ther. 1996 Jun; 3(6):513-20.
View in: PubMed

Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med. 1996 May; 2(5):567-73.
View in: PubMed

In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther. 1996 Apr 10; 7(6):713-20.
View in: PubMed

Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res. 1996 Mar 15; 56(6):1331-40.
View in: PubMed

Activation of protein kinase Cdelta in human myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. Blood. 1996 Mar 01; 87(5):1990-6.
View in: PubMed

Selective effects of DNA damaging agents on HIV long terminal repeat activation and virus replication in vitro. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Feb 01; 11(2):109-16.
View in: PubMed

Identification of a nucleolin binding site in human topoisomerase I. J Biol Chem. 1996 Jan 26; 271(4):1993-7.
View in: PubMed

C-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure. J Biol Chem. 1995 Dec 22; 270(51):30303-9.
View in: PubMed

c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-beta-D-arabinofuranosylcytosine. J Biol Chem. 1995 Dec 22; 270(51):30278-81.
View in: PubMed

Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest. 1995 Dec; 96(6):2775-82.
View in: PubMed

Involvement of stress-activated protein kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Cell Growth Differ. 1995 Dec; 6(12):1651-8.
View in: PubMed

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med. 1995 Dec 01; 182(6):1801-6.
View in: PubMed

Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother. 1995 Oct; 41(4):227-35.
View in: PubMed

Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res. 1995 Sep 15; 55(18):4000-3.
View in: PubMed

Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy. Cancer J Sci Am. 1995 Sep-Oct; 1(3):204-9.
View in: PubMed

Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature. 1995 Aug 31; 376(6543):785-8.
View in: PubMed

Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995 Aug; 1(8):786-91.
View in: PubMed

Defective induction of stress-activated protein kinase activity in ataxia-telangiectasia cells exposed to ionizing radiation. Cancer Res. 1995 Aug 01; 55(15):3242-5.
View in: PubMed

Stimulation of human monocytes with macrophage colony-stimulating factor induces a Grb2-mediated association of the focal adhesion kinase pp125FAK and dynamin. Proc Natl Acad Sci U S A. 1995 Jun 20; 92(13):6132-6.
View in: PubMed

Monocyte colony-stimulating factor stimulates binding of phosphatidylinositol 3-kinase to Grb2.Sos complexes in human monocytes. J Biol Chem. 1995 May 05; 270(18):10380-3.
View in: PubMed

Expression of the DF3-P epitope in human ovarian carcinomas. Clin Cancer Res. 1995 May; 1(5):565-71.
View in: PubMed

Activation of serine/threonine protein kinases and early growth response 1 gene expression by tumor necrosis factor in human myeloid leukemia cells. J Immunol. 1995 Apr 15; 154(8):4150-6.
View in: PubMed

1-beta-D-arabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells. Biochemistry. 1995 Apr 11; 34(14):4908.
View in: PubMed

Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ. 1995 Apr; 6(4):363-70.
View in: PubMed

Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res. 1995 Mar 01; 55(5):991-4.
View in: PubMed

1-beta-D-arabinofuranosylcytosine activates tyrosine phosphorylation of p34cdc2 and its association with the Src-like p56/p53lyn kinase in human myeloid leukemia cells. Biochemistry. 1995 Jan 24; 34(3):1058-63.
View in: PubMed

Cyclocreatine in cancer chemotherapy. Cancer Chemother Pharmacol. 1995; 35(5):411-6.
View in: PubMed

Cellular and molecular mechanisms of radioresistance. Cancer Treat Res. 1995; 74:131-40.
View in: PubMed

Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood. 1994 Nov 01; 84(9):3113-21.
View in: PubMed

Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 1994 Oct 15; 54(20):5408-13.
View in: PubMed

p56/p53lyn tyrosine kinase activation in mammalian cells treated with mitomycin C. Oncogene. 1994 Oct; 9(10):3005-11.
View in: PubMed

Identification of upstream signals regulating interleukin-6 gene expression during in vitro treatment of human B cells with pokeweed mitogen. Blood. 1994 Oct 01; 84(7):2243-52.
View in: PubMed

Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res. 1994 Oct; 18(10):769-76.
View in: PubMed

Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin. Eur J Haematol. 1994 Sep; 53(3):135-44.
View in: PubMed

Radiation induction of immediate early genes: effectors of the radiation-stress response. Int J Radiat Oncol Biol Phys. 1994 Aug 30; 30(1):229-34.
View in: PubMed

Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res. 1994 Aug 15; 54(16):4266-9.
View in: PubMed

Activation of Src-like p56/p53lyn tyrosine kinase by ionizing radiation. J Biol Chem. 1994 Aug 12; 269(32):20739-43.
View in: PubMed

Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol. 1994 Aug 03; 48(3):609-12.
View in: PubMed

Ketoconazole attenuates radiation-induction of tumor necrosis factor. Int J Radiat Oncol Biol Phys. 1994 Jul 01; 29(4):777-80.
View in: PubMed

1-beta-D-arabinofuranosylcytosine activates serine/threonine protein kinases and c-jun gene expression in phorbol ester-resistant myeloid leukemia cells. Mol Pharmacol. 1994 Jul; 46(1):67-72.
View in: PubMed

Activation of the pp90rsk and mitogen-activated serine/threonine protein kinases by ionizing radiation. Proc Natl Acad Sci U S A. 1994 Jun 07; 91(12):5416-20.
View in: PubMed

The role of intracellular calcium in the cellular response to ionizing radiation. Radiat Res. 1994 Jun; 138(3):392-400.
View in: PubMed

Membrane-derived second messenger regulates x-ray-mediated tumor necrosis factor alpha gene induction. Proc Natl Acad Sci U S A. 1994 May 24; 91(11):4897-901.
View in: PubMed

Involvement of serum response element in okadaic acid-induced EGR-1 transcription in human T-cells. Cancer Res. 1994 Apr 15; 54(8):2234-9.
View in: PubMed

Ionizing radiation induces rapid tyrosine phosphorylation of p34cdc2. Cancer Res. 1994 Mar 15; 54(6):1412-4.
View in: PubMed

Activation of early growth response 1 gene transcription and pp90rsk during induction of monocytic differentiation. Cell Growth Differ. 1994 Mar; 5(3):259-65.
View in: PubMed

Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J Biol Chem. 1994 Jan 28; 269(4):2433-9.
View in: PubMed

All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood. 1994 Jan 15; 83(2):490-6.
View in: PubMed

Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells. J Biol Chem. 1994 Jan 14; 269(2):872-8.
View in: PubMed

Localization of tumor-associated glycoprotein DF3 in normal, inflammatory, and neoplastic lesions of the colon. Cancer. 1993 Dec 01; 72(11):3185-90.
View in: PubMed

Coinduction of c-jun gene expression and internucleosomal DNA fragmentation by ionizing radiation. Biochemistry. 1993 Oct 12; 32(40):10607-13.
View in: PubMed

Activation of the early growth response 1 gene and nuclear pp90rsk in human myeloid leukemia cells by 1-(beta-D-arabinofuranosyl)cytosine. Biochemistry. 1993 Sep 07; 32(35):9137-42.
View in: PubMed

Resistance to phorbol ester-induced differentiation of a U-937 myeloid leukemia cell variant with a signaling defect upstream to Raf-1 kinase. Cell Growth Differ. 1993 Aug; 4(8):657-63.
View in: PubMed

Defective translocation of protein kinase C in multidrug-resistant HL-60 cells confers a reversible loss of phorbol ester-induced monocytic differentiation. J Biol Chem. 1993 Jun 15; 268(17):12267-73.
View in: PubMed

Immunohistochemical detection and significance of axillary lymph node micrometastases in breast carcinoma. A study of 97 cases. Anal Quant Cytol Histol. 1993 Jun; 15(3):171-8.
View in: PubMed

Activation of the jun-D gene during treatment of human myeloid leukemia cells with 1-beta-D-arabinofuranosylcytosine. Biochem Pharmacol. 1993 May 25; 45(10):2055-61.
View in: PubMed

Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol. 1993 Apr; 16(2):159-63.
View in: PubMed

Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci U S A. 1993 Mar 15; 90(6):2419-22.
View in: PubMed

Regulation of c-jun gene expression in human T lymphocytes. Blood. 1993 Mar 15; 81(6):1540-8.
View in: PubMed

Radiation signaling mediated by Jun activation following dissociation from a cell type-specific repressor. J Biol Chem. 1993 Mar 05; 268(7):4903-7.
View in: PubMed

Phorbol ester-induced monocytic differentiation is associated with G2 delay and down-regulation of cdc25 expression. Cell Growth Differ. 1993 Mar; 4(3):159-66.
View in: PubMed

Induction of the c-jun proto-oncogene by a protein kinase C-dependent mechanism during exposure of human epidermal keratinocytes to ethanol. Biochem Pharmacol. 1993 Feb 09; 45(3):675-81.
View in: PubMed

Ionizing radiation down-regulates histone H1 gene expression by transcriptional and post-transcriptional mechanisms. Radiat Res. 1993 Feb; 133(2):176-81.
View in: PubMed

Effect of Bcl-2 on ionizing radiation and 1-beta-D-arabinofuranosylcytosine-induced internucleosomal DNA fragmentation and cell survival in human myeloid leukemia cells. Oncol Res. 1993; 5(3):139-44.
View in: PubMed

Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc Natl Acad Sci U S A. 1993 Jan 01; 90(1):282-6.
View in: PubMed

Transcriptional regulation of the early growth response 1 gene in human myeloid leukemia cells by okadaic acid. Cell Growth Differ. 1993 Jan; 4(1):17-23.
View in: PubMed

The role of cytokines in radiation oncology. Important Adv Oncol. 1993; 71-80.
View in: PubMed

Macrophage colony stimulating factor activates phosphatidylcholine hydrolysis by cytoplasmic phospholipase A2. EMBO J. 1992 Dec; 11(13):4917-22.
View in: PubMed

Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope. Cancer Res. 1992 Nov 15; 52(22):6365-70.
View in: PubMed

Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood. 1992 Nov 15; 80(10):2604-9.
View in: PubMed

Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10149-53.
View in: PubMed

Inhibition of EGR-1 and NF-kappa B gene expression by dexamethasone during phorbol ester-induced human monocytic differentiation. Biochem Pharmacol. 1992 Oct 20; 44(8):1569-76.
View in: PubMed

Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. Biochemistry. 1992 Sep 08; 31(35):8300-6.
View in: PubMed

Down-regulation of cell cycle control genes by ionizing radiation. Cell Growth Differ. 1992 Sep; 3(9):637-44.
View in: PubMed

Molecular targets to overcome radioresistance. Semin Oncol. 1992 Aug; 19(4 Suppl 11):14-20.
View in: PubMed

Future of basic/clinical hematopoiesis research in the era of hematopoietic growth factor availability. Semin Oncol. 1992 Aug; 19(4):441-8.
View in: PubMed

Transcriptional regulation of cytokine expression by diethyldithiocarbamate in human HL-60 promyelocytic leukemia cells. Biochem Pharmacol. 1992 Jul 22; 44(2):365-71.
View in: PubMed

Regulation of c-jun expression during induction of monocytic differentiation by okadaic acid. Cell Growth Differ. 1992 Jul; 3(7):391-9.
View in: PubMed

Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res. 1992 May 01; 52(9):2563-8.
View in: PubMed

Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992 May; 92(5):495-502.
View in: PubMed

Identification of NF-jun, a novel inducible transcription factor that regulates c-jun gene transcription. EMBO J. 1992 Apr; 11(4):1479-86.
View in: PubMed

Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle-regulatory genes. Cancer Res. 1992 Mar 15; 52(6):1445-50.
View in: PubMed

Internucleosomal DNA fragmentation during phorbol ester-induced monocytic differentiation and G0/G1 arrest. J Clin Invest. 1992 Mar; 89(3):954-60.
View in: PubMed

cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway. Cancer Res. 1992 Feb 15; 52(4):878-82.
View in: PubMed

Functional expression of the macrophage colony-stimulating factor receptor in human THP-1 monocytic leukemia cells. Blood. 1992 Feb 15; 79(4):904-12.
View in: PubMed

Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992 Feb; 140(2):301-16.
View in: PubMed

Activation of the AP-1 transcription factor by arabinofuranosylcytosine in myeloid leukemia cells. Blood. 1992 Feb 01; 79(3):728-34.
View in: PubMed

Activation of the transcription factor kappa B in human KG-1 myeloid leukemia cells treated with 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 1992 Jan; 41(1):60-3.
View in: PubMed

Transcriptional and posttranscriptional regulation of H1 histone gene expression by 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 1992 Jan; 41(1):64-8.
View in: PubMed

Immunocytochemical determination of the estrogen-regulated proteins Mr 24,000, Mr 52,000 and DF3 breast cancer associated antigen: clinical value in advanced breast cancer and correlation with estrogen receptor. Ann Oncol. 1992 Jan; 3(1):71-7.
View in: PubMed

Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor. Mediators Inflamm. 1992; 1(4):235-40.
View in: PubMed

Gene therapy targeted by ionizing radiation. Int J Radiat Oncol Biol Phys. 1992; 24(3):565-7.
View in: PubMed

Genomic structure, induction, and production of TNF-alpha. Immunol Ser. 1992; 56:3-34.
View in: PubMed

Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res. 1991 Dec 15; 51(24):6636-42.
View in: PubMed

Inhibition of protein kinase C is associated with a decrease in c-myc expression in human myeloid leukemia cells. FEBS Lett. 1991 Dec 02; 294(1-2):73-6.
View in: PubMed

A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120. Proc Natl Acad Sci U S A. 1991 Dec 01; 88(23):10726-9.
View in: PubMed

Protein kinase C activation and protooncogene expression in differentiation/retrodifferentiation of human U-937 leukemia cells. Cell Growth Differ. 1991 Nov; 2(11):541-8.
View in: PubMed

Mechanisms of X-ray-mediated protooncogene c-jun expression in radiation-induced human sarcoma cell lines. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1677-81.
View in: PubMed

Involvement of a nuclear factor-kappa B-like protein in induction of the macrophage colony-stimulating factor gene by tumor necrosis factor. Blood. 1991 Oct 15; 78(8):1988-95.
View in: PubMed

Inhibition of phorbol ester-induced monocytic differentiation by dexamethasone is associated with down-regulation of c-fos and c-jun (AP-1). J Cell Physiol. 1991 Oct; 149(1):125-31.
View in: PubMed

Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. Cancer Res. 1991 Sep 01; 51(17):4565-9.
View in: PubMed

Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. 1991 Aug 15; 51(16):4476-80.
View in: PubMed

Regulation of c-jun gene expression in HL-60 leukemia cells by 1-beta-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism. Biochemistry. 1991 Aug 13; 30(32):7947-52.
View in: PubMed

Lung cancer-associated protein: development and characterization of a new assay that detects a circulating lung cancer marker. Cancer Res. 1991 Aug 01; 51(15):3838-42.
View in: PubMed

Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest. 1991 Aug; 88(2):691-5.
View in: PubMed

Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest. 1991 Aug; 88(2):571-7.
View in: PubMed

Effects of hexamethylene bisacetamide on induction of monocytic differentiation of human U-937 myeloid leukemia cells. Biochem Pharmacol. 1991 Jul 05; 42(2):403-7.
View in: PubMed

Regulation of jun-B expression by a cyclic AMP (cAMP)-dependent mechanism in human myeloid cells. Blood. 1991 Jul 01; 78(1):83-8.
View in: PubMed

Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol. 1991 Jun; 39(6):697-701.
View in: PubMed

Regulation of jun and fos gene expression in human monocytes by the macrophage colony-stimulating factor. Cell Growth Differ. 1991 Jun; 2(6):267-72.
View in: PubMed

Posttranscriptional regulation of the zinc finger-encoding EGR-1 gene by granulocyte-macrophage colony-stimulating factor in human U-937 monocytic leukemia cells: involvement of a pertussis toxin-sensitive G protein. Cell Growth Differ. 1991 Jun; 2(6):273-8.
View in: PubMed

Shaking HIV-1 infected cells indicates novel behavior of MN strain. AIDS Res Hum Retroviruses. 1991 May; 7(5):459-63.
View in: PubMed

Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J Clin Invest. 1991 May; 87(5):1794-7.
View in: PubMed

Biological consequences of gene regulation after ionizing radiation exposure. J Natl Cancer Inst. 1991 Apr 03; 83(7):480-4.
View in: PubMed

Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci U S A. 1991 Mar 15; 88(6):2156-60.
View in: PubMed

Coexpression of the genes for platelet-derived growth factor B-chain receptor and macrophage colony-stimulating factor 1 receptor during monocytic differentiation. Proc Natl Acad Sci U S A. 1991 Mar 15; 88(6):2481-5.
View in: PubMed

Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1991 Jan 15; 51(2):741-3.
View in: PubMed

CSFs in combination with cytosine arabinoside, an inhibitor of DNA synthesis: potential strategies for the treatment of myeloid disorders. Biotechnol Ther. 1991; 2(3-4):269-83.
View in: PubMed

Expression of the jun-B gene during induction of monocytic differentiation. Cell Growth Differ. 1991 Jan; 2(1):43-9.
View in: PubMed

Effects of granulocyte-macrophage colony-stimulating factor on 3'-azido-3'-deoxythymidine uptake, phosphorylation and nucleotide retention in human U-937 cells. Biochem Pharmacol. 1990 Dec 15; 40(12):2695-700.
View in: PubMed

Regulation of c-jun gene expression by cAMP in HL-60 myeloid leukemia cells. J Biol Chem. 1990 Dec 15; 265(35):22011-5.
View in: PubMed

A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Leukemia. 1990 Dec; 4(12):843-7.
View in: PubMed

Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res. 1990 Nov 15; 50(22):7101-7.
View in: PubMed

Transcriptional regulation of c-jun gene expression by arabinofuranosylcytosine in human myeloid leukemia cells. J Clin Invest. 1990 Nov; 86(5):1517-23.
View in: PubMed

Detection and characterization of a high molecular weight human lung carcinoma-associated glycoprotein. Cancer Res. 1990 Oct 15; 50(20):6738-43.
View in: PubMed

Regulation of jun-B gene expression by 1-beta-D-arabinofuranosyl-cytosine in human myeloid leukemia cells. Mol Pharmacol. 1990 Oct; 38(4):435-9.
View in: PubMed

Inhibition of phorbol ester-induced monocytic differentiation and c-fms gene expression by dexamethasone: potential involvement of arachidonic acid metabolites. Blood. 1990 Sep 15; 76(6):1225-32.
View in: PubMed

DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody-coated targets. J Immunol. 1990 Aug 01; 145(3):962-70.
View in: PubMed

Colony-stimulating factor 1 activates protein kinase C in human monocytes. EMBO J. 1990 Aug; 9(8):2423-8, 2389.
View in: PubMed

Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci U S A. 1990 Aug; 87(15):5663-6.
View in: PubMed

Regulation of proto-oncogene and tumor necrosis factor gene expression by ethanol in HL-60 myeloid leukemia cells. Blood. 1990 Jul 15; 76(2):298-301.
View in: PubMed

The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys. 1990 Jul; 19(1):69-74.
View in: PubMed

Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells. J Cell Physiol. 1990 May; 143(2):226-31.
View in: PubMed

Effects of lipopolysaccharide on phospholipase A2 activity and tumor necrosis factor expression in HL-60 cells. J Immunol. 1990 Apr 01; 144(7):2678-82.
View in: PubMed

Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells. J Biol Chem. 1990 Feb 25; 265(6):3320-3.
View in: PubMed

Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res. 1990 Feb 15; 50(4):1170-5.
View in: PubMed

Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells. Blood. 1990 Feb 01; 75(3):583-8.
View in: PubMed

Effects of dexamethasone on induction of monocytic differentiation in human U-937 cells by dimethylsulfoxide. J Cell Physiol. 1990 Feb; 142(2):261-7.
View in: PubMed

Transcriptional and posttranscriptional regulation of macrophage-specific colony stimulating factor gene expression by tumor necrosis factor. Involvement of arachidonic acid metabolites. J Clin Invest. 1990 Feb; 85(2):442-7.
View in: PubMed

Induction of c-fos gene expression by arabinofuranosylcytosine in human KG-1 leukemia cells. Cancer Commun. 1990; 2(12):409-14.
View in: PubMed

Induction of monocytic differentiation by tumor necrosis factor in phorbol ester-resistant KG-1a cells. Cancer Commun. 1990; 2(10):327-32.
View in: PubMed

Sequence analysis of the 5' region of the human DF3 breast carcinoma-associated antigen gene. Biochem Biophys Res Commun. 1989 Dec 15; 165(2):644-9.
View in: PubMed

Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res. 1989 Dec 15; 49(24 Pt 1):6966-71.
View in: PubMed

Circulating tumor markers in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):653-74.
View in: PubMed

Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A. 1989 Dec; 86(24):10104-7.
View in: PubMed

A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. J Clin Oncol. 1989 Oct; 7(10):1545-53.
View in: PubMed

Downregulation of c-fms gene expression in human monocytes treated with phorbol esters and colony-stimulating factor 1. Blood. 1989 Jul; 74(1):123-9.
View in: PubMed

Structural analysis of the DF3 human breast carcinoma-associated protein. Cancer Res. 1989 Jun 01; 49(11):2834-9.
View in: PubMed

Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med. 1989 Jun 01; 169(6):2257-62.
View in: PubMed

Effects of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes. Mol Cell Biol. 1989 May; 9(5):2239-43.
View in: PubMed

Sequence-specific inhibition of DNA strand elongation by incorporation of 9-beta-D-arabinofuranosyladenine. Cancer Res. 1989 Apr 15; 49(8):2077-81.
View in: PubMed

Posttranscriptional stabilization of c-fms mRNA by a labile protein during human monocytic differentiation. Mol Cell Biol. 1989 Feb; 9(2):769-75.
View in: PubMed

Tiazofurin induction of mouse erythroleukemia cell hemoglobin production in the absence of commitment or changes in protooncogene expression. Blood. 1989 Feb; 73(2):431-4.
View in: PubMed

Effects of tiazofurin on globin and proto-oncogene expression in K562 erythroleukemia cells. Cancer Commun. 1989; 1(3):191-7.
View in: PubMed

Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun. 1989; 1(4):261-7.
View in: PubMed

Detection of tumor necrosis factor gene expression at a cellular level in human acute myeloid leukemias. Leukemia. 1989 Jan; 3(1):51-6.
View in: PubMed

Role of arachidonic acid metabolism in transcriptional induction of tumor necrosis factor gene expression by phorbol ester. Mol Cell Biol. 1989 Jan; 9(1):252-8.
View in: PubMed

CSF-1 and C-FMS gene expression in human carcinoma cell lines. Biochem Biophys Res Commun. 1988 Nov 30; 157(1):395-401.
View in: PubMed

Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation. Cancer Res. 1988 Nov 01; 48(21):5965-8.
View in: PubMed

Colony-stimulating factor 1-induced Na+ influx into human monocytes involves activation of a pertussis toxin-sensitive GTP-binding protein. J Biol Chem. 1988 Oct 05; 263(28):14093-8.
View in: PubMed

Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines. J Clin Invest. 1988 Oct; 82(4):1157-64.
View in: PubMed

Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst. 1988 Sep 07; 80(13):1039-44.
View in: PubMed

Transcriptional and posttranscriptional regulation of CSF-1 gene expression in human monocytes. Mol Cell Biol. 1988 Sep; 8(9):3951-4.
View in: PubMed

Expression of the platelet-derived growth factor 1 and 2 genes in human myeloid cell lines and monocytes. Cancer Res. 1988 Aug 15; 48(16):4498-502.
View in: PubMed

Phospholipase C activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Aug; 72(2):739-44.
View in: PubMed

Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells. J Biol Chem. 1988 Jul 25; 263(21):10247-53.
View in: PubMed

Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res. 1988 Jul 15; 48(14):4107-12.
View in: PubMed

Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 1988 Jul; 72(1):208-13.
View in: PubMed

Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest. 1988 May; 81(5):1506-10.
View in: PubMed

Prolonged high dose ARA-C infusions in acute leukemia. Leukemia. 1988 May; 2(5):304-6.
View in: PubMed

Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow. Breast Cancer Res Treat. 1988 May; 11(2):133-45.
View in: PubMed

Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci U S A. 1988 Apr; 85(7):2320-3.
View in: PubMed

Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest. 1988 Apr; 81(4):1030-5.
View in: PubMed

Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta. Cancer Res. 1988 Mar 15; 48(6):1494-8.
View in: PubMed

Modulation of cyclic AMP levels and differentiation by adenosine analogs in mouse erythroleukemia cells. J Cell Physiol. 1988 Mar; 134(3):429-36.
View in: PubMed

Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest. 1988 Feb; 81(2):455-60.
View in: PubMed

c-sis but not c-fos gene expression is lineage specific in human myeloid cells. Blood. 1988 Feb; 71(2):488-93.
View in: PubMed

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol. 1988 Feb; 6(2):344-50.
View in: PubMed

Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen. Blood. 1988 Feb; 71(2):436-40.
View in: PubMed

Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells. Int J Rad Appl Instrum B. 1988; 15(3):235-41.
View in: PubMed

Transcriptional and posttranscriptional control of c-fos gene expression in human monocytes. Mol Cell Biol. 1988 Jan; 8(1):340-6.
View in: PubMed

Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res. 1987 Dec 15; 47(24 Pt 1):6532-6.
View in: PubMed

Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J Immunol. 1987 Nov 01; 139(9):2989-92.
View in: PubMed

Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci U S A. 1987 Sep; 84(18):6563-6.
View in: PubMed

Identification of a family of high molecular weight tumor-associated glycoproteins. J Immunol. 1987 Jul 01; 139(1):257-61.
View in: PubMed

Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast. J Natl Cancer Inst. 1987 Jul; 79(1):109-17.
View in: PubMed

Detection of c-fms and CSF-1 RNA by in situ hybridization. Leukemia. 1987 Jun; 1(6):518-20.
View in: PubMed

Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest. 1987 Jun; 79(6):1720-8.
View in: PubMed

Pharmacologic studies of low-dose and high-dose continuous infusion cytosine arabinoside. Semin Oncol. 1987 Jun; 14(2 Suppl 1):149-58.
View in: PubMed

Expression of the c-raf protooncogene in human hematopoietic cells and cell lines. Blood. 1987 May; 69(5):1437-40.
View in: PubMed

Tumor-associated antigens in bilateral breast cancer. J Surg Oncol. 1987 May; 35(1):24-9.
View in: PubMed

Expression of the macrophage-specific colony-stimulating factor in human monocytes treated with granulocyte-macrophage colony-stimulating factor. Blood. 1987 Apr; 69(4):1259-61.
View in: PubMed

Effects of interferon-gamma on proto-oncogene expression during induction of human monocytic differentiation. J Immunol. 1987 Mar 15; 138(6):1954-8.
View in: PubMed

Southern blot analysis of BII cell line--a putative variant of HL-60. Leukemia. 1987 Feb; 1(2):142-5.
View in: PubMed

Clinical studies with tumour necrosis factor. Ciba Found Symp. 1987; 131:206-27.
View in: PubMed

Expression of the macrophage specific colony-stimulating factor (CSF-1) during human monocytic differentiation. Biochem Biophys Res Commun. 1986 Dec 30; 141(3):924-30.
View in: PubMed

Effects of cis-diamminedichloroplatinum on DNA incorporation and cytotoxicity of 1-beta-D-arabinofuranosylcytosine. Biochem Pharmacol. 1986 Dec 01; 35(23):4297-302.
View in: PubMed

Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986 Nov; 46(11):5953-8.
View in: PubMed

The treatment of myelodysplastic syndromes. Clin Haematol. 1986 Nov; 15(4):1081-107.
View in: PubMed

Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986 Oct; 4(10):1542-50.
View in: PubMed

Effects of 1-beta-D-arabinofuranosylcytosine on proto-oncogene expression in human U-937 cells. Mol Pharmacol. 1986 Oct; 30(4):398-402.
View in: PubMed

Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res. 1986 Oct; 46(10):5189-94.
View in: PubMed

Induction of c-sis gene expression and synthesis of platelet-derived growth factor in human myeloid leukemia cells during monocytic differentiation. Proc Natl Acad Sci U S A. 1986 Sep; 83(17):6455-9.
View in: PubMed

Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res. 1986 Sep; 46(9):4534-8.
View in: PubMed

Selective inhibition of spermidine biosynthesis and differentiation by S-adenosyl-1,8-diamino-3-thiooctane in murine erythroleukemia cells. Biochem Pharmacol. 1986 Aug 01; 35(15):2633-6.
View in: PubMed

Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. Cancer Res. 1986 Jun; 46(6):3157-63.
View in: PubMed

Effects of ornithine decarboxylase inhibition on c-myc expression during murine erythroleukemia cell proliferation and differentiation. J Cell Physiol. 1986 Jun; 127(3):480-4.
View in: PubMed

Effects of 5-fluorouracil on globin mRNA synthesis in murine erythroleukemia cells. Biochemistry. 1986 May 06; 25(9):2703-7.
View in: PubMed

Inhibitory effects of theophylline and dibutyryl cAMP on murine erythroleukemia cell differentiation. Biochem Biophys Res Commun. 1986 Jan 29; 134(2):845-51.
View in: PubMed

Incorporation of 9-beta-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem Pharmacol. 1986 Jan 15; 35(2):247-52.
View in: PubMed

Effects of maturational agents on expression and secretion of two partially characterized high molecular weight milk-related glycoproteins in MCF-7 breast carcinoma cells. J Cell Physiol. 1986 Jan; 126(1):126-32.
View in: PubMed

Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation. Cancer Drug Deliv. 1986; 3(3):211-6.
View in: PubMed

TPA induces differentiation of purified human myeloblasts in the absence of proliferation. Exp Hematol. 1985 Nov; 13(10):1025-32.
View in: PubMed

Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol. 1985 Nov; 135(5):3610-5.
View in: PubMed

Inhibition of murine erythroleukemia cell differentiation by 3-deazaadenosine. Cancer Res. 1985 Nov; 45(11 Pt 2):5830-4.
View in: PubMed

Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol. 1985 Oct; 3(10):1355-63.
View in: PubMed

Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study. Cancer Res. 1985 Aug; 45(8):3932-6.
View in: PubMed

Effect of 1-beta-D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts. Biochem Pharmacol. 1985 Jul 15; 34(14):2557-60.
View in: PubMed

Expression of the c-fms proto-oncogene during human monocytic differentiation. Nature. 1985 Jul 4-10; 316(6023):64-6.
View in: PubMed

Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside. J Clin Oncol. 1985 Jul; 3(7):982-91.
View in: PubMed

Biochemical and cellular pharmacology of cytosine arabinoside. Semin Oncol. 1985 Jun; 12(2 Suppl 3):34-48.
View in: PubMed

Cellular and clinical pharmacology of low-dose ara-C. Semin Oncol. 1985 Jun; 12(2 Suppl 3):200-7.
View in: PubMed

Effects of 1-beta-D-arabinofuranosylcytosine and phorbol ester on differentiation of human K562 erythroleukemia cells. Mol Pharmacol. 1985 Jun; 27(6):683-8.
View in: PubMed

Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest. 1985 May; 75(5):1671-8.
View in: PubMed

Clinical pharmacology of low-dose cytosine arabinoside. Blood. 1985 May; 65(5):1087-9.
View in: PubMed

Requirement of spermidine for induction of both heme synthesis and globin transcription in murine erythroleukemia cells. J Cell Physiol. 1985 Mar; 122(3):435-40.
View in: PubMed

Human c-myc and N-ras expression during induction of HL-60 cellular differentiation. Biochem Biophys Res Commun. 1985 Feb 15; 126(3):999-1005.
View in: PubMed

Inhibition of DNA excision repair and the repair of X-ray-induced DNA damage by cytosine arabinoside and hydroxyurea. Pharmacol Ther. 1985; 31(3):165-76.
View in: PubMed

Radioiodinated B6.2 monoclonal antibody: further characterization of a potential radiopharmaceutical for the identification of breast tumors. Int J Nucl Med Biol. 1985; 12(3):227-33.
View in: PubMed

Monoclonal antibodies reactive with breast tumor-associated antigens. Adv Cancer Res. 1985; 43:143-73.
View in: PubMed

Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. Breast Cancer Res Treat. 1985; 5(3):269-76.
View in: PubMed

Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer. Cancer. 1984 Dec 01; 54(11 Suppl):2777-94.
View in: PubMed

Effect of 5'-methylthioadenosine on induction of murine erythroleukemia cell differentiation. Biochem Biophys Res Commun. 1984 Oct 15; 124(1):172-7.
View in: PubMed

Polyamine requirements for induction of HL-60 promyelocyte differentiation by leukocyte-conditioned medium and phorbol ester. Cancer Res. 1984 Oct; 44(10):4281-4.
View in: PubMed

Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells. Cancer Res. 1984 Oct; 44(10):4574-7.
View in: PubMed

Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. J Clin Invest. 1984 Sep; 74(3):821-7.
View in: PubMed

DNA strand scission and ADP-ribosyltransferase activity during murine erythroleukemia cell differentiation. Dev Biol. 1984 Aug; 104(2):484-8.
View in: PubMed

Uracil enhancement of 5-fluorodexoyuridine incorporation into human breast carcinoma deoxyribonucleic acid. Biochem Pharmacol. 1984 Jul 15; 33(14):2329-31.
View in: PubMed

Lethality associated with incorporation of 5-fluorouracil into preribosomal RNA. Mol Pharmacol. 1984 Jul; 26(1):135-40.
View in: PubMed

Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. Acta Cytol. 1984 Jul-Aug; 28(4):356-67.
View in: PubMed

Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol Pharmacol. 1984 Jul; 26(1):128-34.
View in: PubMed

Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood. 1984 Jul; 64(1):54-8.
View in: PubMed

Involvement of spermidine in proliferation and differentiation of human promyelocytic leukemia cells. Blood. 1984 May; 63(5):1153-8.
View in: PubMed

Effects of polyamine depletion on proliferation and differentiation of murine erythroleukemia cells. Cancer Res. 1984 Apr; 44(4):1440-4.
View in: PubMed

Lethal effects of 1-beta-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair. Mol Pharmacol. 1984 Mar; 25(2):322-6.
View in: PubMed

The effect of inhibitors of DNA synthesis on DNA repair. Nucleic Acids Symp Ser. 1984; (13):95-107.
View in: PubMed

Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA from herpes simplex virus resistant to 9-beta-D-arabinofuranosyladenine. Cancer Res. 1984 Jan; 44(1):69-73.
View in: PubMed

Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU. Cancer Chemother Pharmacol. 1984; 13(2):136-8.
View in: PubMed

Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma. 1984; 3(3):223-32.
View in: PubMed

Effect of sodium butyrate on human breast carcinoma (MCF-7) cellular proliferation, morphology, and CEA production. Breast Cancer Res Treat. 1984; 4(4):269-74.
View in: PubMed

Effect of ara-A on differentiation and proliferation of HL-60 cells. Leuk Res. 1984; 8(3):355-61.
View in: PubMed

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med. 1983 Dec 29; 309(26):1599-602.
View in: PubMed

Alkali lability of deoxyribonucleic acid that contains adenine arabinoside. Biochem Pharmacol. 1983 Dec 15; 32(24):3849-52.
View in: PubMed

Generation time of leukaemic blast progenitor cells. Cell Tissue Kinet. 1983 Nov; 16(6):577-82.
View in: PubMed

Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity. Cancer Res. 1983 May; 43(5):2000-4.
View in: PubMed

Biologic effect of 5-fluoro-2'-deoxyuridine incorporation in L1210 deoxyribonucleic acid. Biochem Pharmacol. 1983 Apr 15; 32(8):1337-40.
View in: PubMed

Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res. 1983 Feb; 43(2):736-42.
View in: PubMed

Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res. 1983 Feb; 43(2):851-7.
View in: PubMed

Monoclonal antibodies to human mammary carcinoma associated antigens and their potential uses for diagnosis, prognosis, and therapy. Lab Res Methods Biol Med. 1983; 8:215-58.
View in: PubMed

Accumulation of leukemic cell DNA strand breaks with adriamycin and cytosine arabinoside. Leuk Res. 1983; 7(2):243-9.
View in: PubMed

Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin. Cancer Chemother Pharmacol. 1983; 10(2):125-8.
View in: PubMed

A phase I-II study of combination therapy with thymidine and cytosine arabinoside. Cancer Chemother Pharmacol. 1983; 11(1):43-7.
View in: PubMed

Effect of methotrexate on incorporation and excision of 5-fluorouracil residues in human breast carcinoma DNA. Cancer Res. 1982 Dec; 42(12):5015-7.
View in: PubMed

Pharmacologic studies on the dibutyl and gamma-monobutyl esters of methotrexate in the rhesus monkey. Cancer Chemother Pharmacol. 1982 Dec; 10(1):55-61.
View in: PubMed

Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol. 1982 Oct; 10(9):774-81.
View in: PubMed

DNA strand breaks caused by inhibitors of DNA synthesis: 1-beta-D-arabinofuranosylcytosine and aphidicolin. Cancer Res. 1982 Oct; 42(10):4050-3.
View in: PubMed

Effect of ARA-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem Pharmacol. 1982 Sep 15; 31(18):2937-40.
View in: PubMed

Simple and rapid high-performance liquid chromatographic method for analysis of nucleosides in biological fluids. J Chromatogr. 1982 Sep 10; 231(2):418-24.
View in: PubMed

Phase I and pharmacological study of acivicin by 24-hour continuous infusion. Cancer Res. 1982 Sep; 42(9):3892-5.
View in: PubMed

5-Fluorouracil incorporation in DNA of human breast carcinoma cells. Cancer Res. 1982 Aug; 42(8):3005-9.
View in: PubMed

Instability of (ara-C) DNA under alkaline conditions. Biochem Pharmacol. 1982 Mar 01; 31(5):861-6.
View in: PubMed

Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. Cancer Treat Rep. 1982 Feb; 66(2):299-303.
View in: PubMed

A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU. Cancer Chemother Pharmacol. 1982; 8(3):301-4.
View in: PubMed

Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells. Cancer Chemother Pharmacol. 1982; 8(1):87-91.
View in: PubMed

Studies on the mechanism of action of cytosine arabinoside. Med Pediatr Oncol. 1982; 10 Suppl 1:49-67.
View in: PubMed

5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem. 1981 Oct 10; 256(19):9802-5.
View in: PubMed

Effect of high-dose thymidine infusions in patients with mycosis fungoides. Cancer. 1981 Oct 01; 48(7):1513-6.
View in: PubMed

5-Fluoro-2'-deoxyuridine incorporation in L1210 DNA. J Biol Chem. 1981 Sep 10; 256(17):8885-8.
View in: PubMed

Rescue of thymidine cytotoxicity in L1210 ascites by elevated endogenous levels of deoxycytidine. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):853-60.
View in: PubMed

Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Sep; 41(9 Pt 1):3419-23.
View in: PubMed

Correlation of thymidine-enhanced incorporation of ara-C in deoxyribonucleic acid with increased cell kill. Biochem Pharmacol. 1981 Aug 15; 30(16):2221-4.
View in: PubMed

Clinical pharmacology of deoxycoformycin. Blood. 1981 Jul; 58(1):91-6.
View in: PubMed

Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc Natl Acad Sci U S A. 1981 May; 78(5):3235-9.
View in: PubMed

Phase I trial of combination therapy with PALA and 5-FU. Cancer Treat Rep. 1981 Mar-Apr; 65(3-4):331-4.
View in: PubMed

Enhancement of 5-fluorouracil incorporation into human lymphoblast ribonucleic acid. Biochem Pharmacol. 1981 Jan 15; 30(2):129-33.
View in: PubMed

A blast subclone of the HL-60 human promyelocytic cell line. Leuk Res. 1981; 5(4-5):429-30.
View in: PubMed

Thymidine 5'-O-pivaloate: evidence for prodrug action in the rat and rhesus monkey. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):93-9.
View in: PubMed

Deoxycoformycin: neurological toxicity. Cancer Chemother Pharmacol. 1981; 5(3):193-6.
View in: PubMed

Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:137-40.
View in: PubMed

Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem. 1980 Oct 10; 255(19):8997-900.
View in: PubMed

Natural resistance to methotrexate in human melanomas. J Invest Dermatol. 1980 Oct; 75(4):357-9.
View in: PubMed

Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1067-71.
View in: PubMed

Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep; 40(9):3147-54.
View in: PubMed

High-dose thymidine infusions in patients with leukemia and lymphoma. Blood. 1980 Apr; 55(4):580-9.
View in: PubMed

Thymidine arrest and synchrony of cellular growth in vivo. Cancer Treat Rep. 1980; 64(12):1307-17.
View in: PubMed

Contrasting characteristics of Marek's disease herpesvirus isolated from chickens with and without avian leukosis virus infection. Intervirology. 1978; 10(1):11-23.
View in: PubMed

Type-specific antigenic determinants on the major external glycoprotein of high- and low-oncogenic murine mammary tumor viruses. J Virol. 1977 Nov; 24(2):525-33.
View in: PubMed

Multiple antigenic determinants on the major surface glycoprotein of murine mammary tumor viruses. Proc Natl Acad Sci U S A. 1977 Aug; 74(8):3564-8.
View in: PubMed

Characterisation of a virus (HL23V) isolated from cultured acute myelogenous leukaemic cells. Nature. 1976 Mar 18; 260(5548):266-8.
View in: PubMed

The molecular genetics of human cancer and its etiologic implications. Genetics. 1975 Jun; 79 Suppl:317-38.
View in: PubMed

Sequences related to the RNA tumor viruses in the RNA and DNA of human leukemias and lymphomas. Bibl Haematol. 1975; (40):3-25.
View in: PubMed

Human cancer and animal viral oncology. Cancer. 1974 Oct; 34(4 Suppl):suppl:1406-20.
View in: PubMed

RNA tumor viruses and human lymphomas. Hamatol Bluttransfus. 1974; 14:164-74.
View in: PubMed

Unique nuclear DNA sequences in the involved tissues of Hodgkin's and Burkitt's lymphomas. Proc Natl Acad Sci U S A. 1973 Dec; 70(12):3810-4.
View in: PubMed

Biological and biochemical evidence for an interaction between Marek's disease herpesvirus and avian leukosis virus in vivo. Proc Natl Acad Sci U S A. 1973 Nov; 70(11):3175-8.
View in: PubMed

A comparative study of the biologic and molecular basis of murine mammary carcinoma: a model for human breast cancer. J Natl Cancer Inst. 1973 Aug; 51(2):541-51.
View in: PubMed

Molecular evidence for a viral etiology of human leukemias, lymphomas, and sarcomas. Am J Clin Pathol. 1973 Jul; 60(1):65-79.
View in: PubMed

Evidence for RNA tumor viruses in human lymphomas including Burkitt's disease. Cancer Res. 1973 Jun; 33(6):1515-26.
View in: PubMed

Burkitt's tumors contain particles encapsulating RNA-instructed DNA polymerase and high molecular weight virus-related RNA. Proc Natl Acad Sci U S A. 1973 Mar; 70(3):737-41.
View in: PubMed

[70S RNA containing particles in human leukemias]. Verh Dtsch Ges Inn Med. 1973; 79:402-5.
View in: PubMed

RNA related to that of a murine leukemia virus in Burkitt's tumors and nasopharyngeal carcinomas. Proc Natl Acad Sci U S A. 1973 Jan; 70(1):5-9.
View in: PubMed

The relevance of RNA tumor viruses to human cancer. Johns Hopkins Med J Suppl. 1973; 2:282-312.
View in: PubMed

Viral-related RNA in Hodgkins' disease and other human lymphomas. Proc Natl Acad Sci U S A. 1972 Jul; 69(7):1727-31.
View in: PubMed

RNA in human leukemic cells related to the RNA of a mouse leukemia virus (leukocytes-RNA-DNA hybridization-rauscher virus-polysomal RNA). Proc Natl Acad Sci U S A. 1972 Feb; 69(2):435-9.
View in: PubMed

Human sarcomas contain RNA related to the RNA of a mouse leukemia virus. Science. 1972 Jan 14; 175(4018):182-5.
View in: PubMed

Proceedings: Genetics and the cancer cell: molecular evidence for a viral etiology of human cancer. Proc Natl Cancer Conf. 1972; 7:21-40.
View in: PubMed

Oxidative phosphorylation in Corynebacterium diphtheriae. Biochim Biophys Acta. 1968 Jan 15; 153(1):291-3.
View in: PubMed